Analysis of patient characteristics and safety of insulin glargine U300 use in 21 359 patients with type‐2 diabetes and chronic kidney disease: DPV registry study
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16245 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Anjaly Vijayan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Insulin Glargine, Renal Insufficiency, Chronic, Hypoglycemic Agents. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi-Aventis Deutschland.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Managing type‐2 diabetes (T2D) in chronic kidney disease (CKD) patients requires consideration of kidney function, and many drugs have not been investigated thoroughly. Clinical studies have demonstrated Glargine U300 (Gla‐300) supports achievement of adequate glycemic control at low hypoglycemia risk. Materials and Method This cross‐sectional study analysed routine data of 21 359 T2D patients with CKD (1786 using Gla‐300; 19 568 without any insulin) from the prospective Diabetes‐Patienten‐Verlaufsdokumentation (DPV) registry to evaluate patient characteristics and safety of Gla‐300 use across different CKD stages.
Results
Patients on Gla‐300 had T2D onset at an earlier age (median age 55.1 vs. 62.3 years), longer diabetes duration (17.3 vs. 11.3 years), higher body weight (91.3 vs. 83.9 kg) and HbA1c levels (7.3% vs. 6.7%) than non‐insulin patients (all p < 0.001). Gla‐300 usage increased from CKD stage 1–4 (median dose 44 vs. 55 units) with higher baseline HbA1c levels (7.2% vs. 7.4%). Although severe hypoglycemia rates were low, a slight increase (0.01%/PY vs. 0.04%/PY) was observed with decreasing estimated glomerular filtration rate levels. Compared to others, stage 5 CKD patients had a distinct profile with lower HbA1c levels (6.9%), body weight (90 kg) and higher Gla‐300 usage (50 units). Metformin, SGLT‐2 inhibitors and GLP‐1 RA were common concomitant drugs with diminished usage in advanced CKD stages, while Gla‐300 was common at all stages.
Conclusion
Despite variations in patient profiles, Gla‐300 is widely used across all CKD stages, particularly in advanced stages with a low rate of severe hypoglycemia, suggesting its safe administration in CKD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany.
- Institute of Epidemiology and Medical Biometry, ZIBMT, University of Ulm, Ulm, Germany.
- German Center for Diabetes Research (DZD), Munich, Germany.
- Diabetes Center Bad Aibling, Bad Aibling, Germany.
- Diabetology Private Practice, Worms, Germany.
- Hellmig Hospital Kamen, Kamen, Germany.
ORCID-Profile: Anjaly Vijayan, Stefanie Lanzinger, Jochen Seufert, Peter Bramlage
Förderung
- Sanofi-Aventis Deutschland
Zitieren
APA
Vijayan, A., Lanzinger, S., Forestier, N., Hess, G., Rottmann, M., Wosch, F. J., Seufert, J., Holl, R. W., Bramlage, P., & DPV (2025). Analysis of patient characteristics and safety of insulin glargine U300 use in 21 359 patients with type‐2 diabetes and chronic kidney disease: DPV registry study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16245
Vancouver
Vijayan A, Lanzinger S, Forestier N, Hess G, Rottmann M, Wosch FJ, et al. Analysis of patient characteristics and safety of insulin glargine U300 use in 21 359 patients with type‐2 diabetes and chronic kidney disease: DPV registry study. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16245
BibTeX
@article{Vijayan2025,
author = {Vijayan, Anjaly and Lanzinger, Stefanie and Forestier, Nicole and Hess, Gregor and Rottmann, Marcus and Wosch, Frank J and Seufert, Jochen and Holl, Reinhard W and Bramlage, Peter and DPV, DPV},
title = {Analysis of patient characteristics and safety of insulin glargine U300 use in 21 359 patients with type‐2 diabetes and chronic kidney disease: DPV registry study},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16245}
}
EUVIMED